You are here
Banding associated with improved comorbidities
According to the one-year results from the Helping Evaluate Reduction in Obesity (HERO) prospective registry, the LAP-BAND AP System (LBAP, Allergan) results in progressive weight loss and is associated with improvement and/or resolution of comorbid conditions. The system was also reported to be safe and well tolerated in patients. The outcomes were published in the Journal of the American College of Surgeons.
The study, which started in December 2009, has enrolled 1,106 patients and will report the changes in weight, waist and hip circumference, blood pressure, HbA1c, fasting glucose, lipid profile, concomitant medications and health-related quality of life.
The current paper reports the one-year data from 834 patients for efficacy analysis. After 12 months, the percentage of excess weight loss (mean) was 39.8 (22.3)%, the percentage of weight loss was 16.9 (9.0)%, and the decreased to 37.7 (7.0) from 45.1 (6.9) at baseline. Patients with type 2 diabetes mellitus or hypertension showed significant improvements at one-year post-LBAP (both p<0.005).
The most common device-related complications were port displacement (n=20 [1.8%]), pouch dilatation (n=12 [1.1%]), band slippage (n=7 [0.6%]), and band erosion (n=5 [0.5%]). A total of 18 (1.6%) patients had the device explanted.
The registry, sponsored by Allergan Medical, is an on-going five-year prospective, observational, international, multicentre registry prospectively assessing the efficacy and safety of LBAP in real-world settings at clinical centres located in North America, Europe, and Australia.